# SAFETY DATA SHEET

**Europe** 

Date of issue/Date of revision

: 15 March 2024

Version



# SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier	
Product name	: FREITAPOX SR 213 EVO BASE GREY
Product code	: 000001199136
Other means of identification	
00473607; 00473608	

1.2 Relevant identified uses of the substance or mixture and uses advised against			
Product use	: Professional applications, Used by spraying.		
Use of the substance/ mixture	: Coating.		
Uses advised against	: Product is not intended, labelled or packaged for consumer use.		

#### 1.3 Details of the supplier of the safety data sheet

**PPG AC - France** Freitag Immeuble Union Square 1, Rue de l'Union CS10055 92565 RUEIL MALMAISON CEDEX France Tel: +33(0)1.57.61.03.20 Fax: +33(0)1.57.61.01.70

e-mail address of person : Product.Stewardship.EMEA@ppg.com responsible for this SDS

#### 1.4 Emergency telephone number

#### **Supplier**

+31 (0)20 4075210

## **SECTION 2: Hazards identification**

#### 2.1 Classification of the substance or mixture

: Mixture

**Product definition** Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS] Flam. Liq. 2, H225 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 STOT RE 2, H373 Aquatic Chronic 3, H412

English (GB)

Europe

1/19

Code: 000001199136Date of issue/Date of revision: 15 March 2024

FREITAPOX SR 213 EVO BASE GREY

### **SECTION 2: Hazards identification**

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

**Hazard pictograms** 

Signal word: DangerHazard statements: Highly flammable liquid and vapour. Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. May cause damage to organs through prolonged or repeated exposure. Harmful to aquatic life with long lasting effects.Prevention: Wear protective gloves. Wear eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Avoid release to the environment. Do not breathe vapour.Response: Get medical advice/attention if you feel unwell.Storage: Not applicable.Disposal: Dispose of contents and container in accordance with all local, regional, national and international regulations. P280, P210, P273, P260, P314, P501Hazardous ingredients: Epoxy Resin (700 MV<=1100) bis-f4-(2.3-epoxipropoxi)phenylpropane crystalline silica, respirable powder (<10 microns) Octadecanois caid, 12-hydroxy-, reaction products with ethylenediamineSupplemental label elements: Not applicable.Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles: Not applicable.Special packaging requirements fastenings Tactle warning of danger: Not applicable.	Hazard pictograms	
Causes skin irritation.       May cause an allergic skin reaction.         Causes serious eye irritation.       May cause damage to organs through prolonged or repeated exposure.         Harmful to aquatic life with long lasting effects.       Prevention         :       Wear protective gloves. Wear eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Avoid release to the environment. Do not breathe vapour.         Response       :       Get medical advice/attention if you feel unwell.         Storage       :       Not applicable.         Dispose of contents and container in accordance with all local, regional, national and international regulations.       P280, P210, P273, P260, P314, P501         Hazardous ingredients       :       Epoxy Resin (700-MW<=1100)         bis/e14-(2,3-epoxipropx)/phenyl/phenylpropane       crystalline silica, respirable powder (<10 microns)         Octadecancic acid, 12-hydroxy-, reaction products with ethylenediamine       Supplemental label         elements       :       Not applicable.         Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles       :         Special packaging requirements       :       Not applicable.         Containers to be fitted with with elements       :       :         Not applicable.       :       :         <	Signal word	: Danger
Response       :       Get medical advice/attention if you feel unwell.         Storage       :       Not applicable.         Disposal       :       Dispose of contents and container in accordance with all local, regional, national and international regulations. P280, P210, P273, P260, P314, P501         Hazardous ingredients       :       Epoxy Resin (700 <mw<=1100) bis-[4-(2,3-epoxipropoxi)phenyl]propane crystalline silica, respirable powder (&lt;10 microns) Octadecanoic acid, 12-hydroxy-, reaction products with ethylenediamine         Supplemental label elements       :       Not applicable.         Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles       :       Not applicable.         Special packaging requirements       :       Not applicable.         Containers to be fitted with child-resistant fastenings       :       Not applicable.</mw<=1100) 	Hazard statements	Causes skin irritation. May cause an allergic skin reaction. Causes serious eye irritation. May cause damage to organs through prolonged or repeated exposure.
Storage       : Not applicable.         Disposal       : Dispose of contents and container in accordance with all local, regional, national and international regulations.         P280, P210, P273, P260, P314, P501         Hazardous ingredients       : Epoxy Resin (700 <mw<=1100) (<10="" 12-hydroxy-,="" acid,="" bis-[4-(2,3-epoxipropoxi)phenyl]propane="" crystalline="" ethylenediamine<="" microns)="" octadecanoic="" powder="" products="" reaction="" respirable="" silica,="" td="" with="">         Supplemental label elements       : Contains epoxy constituents. May produce an allergic reaction.         Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles       : Not applicable.         Special packaging requirements       : Not applicable.         Containers to be fitted with child-resistant fastenings       : Not applicable.</mw<=1100)>	Prevention	surfaces, sparks, open flames and other ignition sources. No smoking. Avoid release to
Disposal       : Dispose of contents and container in accordance with all local, regional, national and international regulations.         P280, P210, P273, P260, P314, P501       : Epoxy Resin (700 <mw<=1100) (<10="" 12-hydroxy-,="" acid,="" bis-[4-(2,3-epoxipropoxi)phenyl]propane="" crystalline="" ethylenediamine<="" microns)="" octadecanoic="" powder="" products="" reaction="" respirable="" silica,="" td="" with="">         Supplemental label elements       : Contains epoxy constituents. May produce an allergic reaction.         Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles       : Not applicable.         Special packaging requirements       : Not applicable.         Containers to be fitted with child-resistant fastenings       : Not applicable.</mw<=1100)>	Response	: Get medical advice/attention if you feel unwell.
international regulations.         P280, P210, P273, P260, P314, P501         Hazardous ingredients       : Epoxy Resin (700 <mw<=1100) bis-[4-(2,3-epoxipropoxi)phenyl]propane crystalline silica, respirable powder (&lt;10 microns) Octadecanoic acid, 12-hydroxy-, reaction products with ethylenediamine         Supplemental label elements       : Contains epoxy constituents. May produce an allergic reaction.         Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles       : Not applicable.         Special packaging requirements       : Not applicable.         Containers to be fitted with child-resistant fastenings       : Not applicable.</mw<=1100) 	Storage	: Not applicable.
bis-[4-(2,3-epoxipropoxi)phenyl]propane         crystalline silica, respirable powder (<10 microns)         Octadecanoic acid, 12-hydroxy-, reaction products with ethylenediamine         Supplemental label       :         elements       :         Annex XVII - Restrictions       :         Not applicable.         on the manufacture,         placing on the market and         use of certain dangerous         substances, mixtures and         articles         Special packaging requirements         Containers to be fitted       :         with child-resistant         fastenings	Disposal	international regulations.
elements Annex XVII - Restrictions : Not applicable. on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles Special packaging requirements Containers to be fitted : Not applicable. with child-resistant fastenings	Hazardous ingredients	bis-[4-(2,3-epoxipropoxi)phenyl]propane crystalline silica, respirable powder (<10 microns)
on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles <u>Special packaging requirements</u> <u>Containers to be fitted</u> : Not applicable. with child-resistant fastenings		: Contains epoxy constituents. May produce an allergic reaction.
Containers to be fitted : Not applicable. with child-resistant fastenings	on the manufacture, placing on the market and use of certain dangerous substances, mixtures and	: Not applicable.
with child-resistant fastenings	Special packaging requirem	ents
Tactile warning of danger : Not applicable.	with child-resistant	: Not applicable.
	Tactile warning of danger	: Not applicable.
2.3 Other hazards	2.3 Other hazards	
<b>Product meets the criteria</b> : This mixture does not contain any substances that are assessed to be a PBT or a vPvB. <b>for PBT or vPvB</b>		: This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do: Prolonged or repeated contact may dry skin and cause irritation.not result in classification		: Prolonged or repeated contact may dry skin and cause irritation.

Code : 000001199136

Date of issue/Date of revision

: 15 March 2024

FREITAPOX SR 213 EVO BASE GREY

## **SECTION 2: Hazards identification**

# **SECTION 3: Composition/information on ingredients**

3.2 Mixtures	: Mixture				
Product/ingredient name	Identifiers	% by weight	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
<b>x</b> ylene	REACH #: 01-2119488216-32 EC: 215-535-7 CAS: 1330-20-7	≥5.0 - ≤10	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	ATE [Dermal] = 1700 mg/kg ATE [Inhalation (vapours)] = 11 mg/l	[1] [2]
o-xylene	REACH #: 01-2119485822-30 EC: 202-422-2 CAS: 95-47-6 Index: 601-022-00-9	≥5.0 - ≤9.9	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	ATE [Dermal] = 1100 mg/kg ATE [Inhalation (vapours)] = 11 mg/l	[1] [2]
Epoxy Resin (700 <mw &lt;=1100)</mw 	CAS: 25036-25-3	≥5.0 - ≤10	Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317	-	[1]
butanone	REACH #: 01-2119457290-43 EC: 201-159-0 CAS: 78-93-3 Index: 606-002-00-3	≥1.0 - ≤5.0	Flam. Liq. 2, H225 Eye Irrit. 2, H319 STOT SE 3, H336 EUH066	-	[1] [2]
bis-[4-(2,3-epoxipropoxi) phenyl]propane	REACH #: 01-2119456619-26 EC: 216-823-5 CAS: 1675-54-3 Index: 603-073-00-2	≥1.0 - ≤5.0	Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 Aquatic Chronic 2, H411	Skin Irrit. 2, H315: C ≥ 5% Eye Irrit. 2, H319: C ≥ 5%	[1]
crystalline silica, respirable powder (<10 microns)	EC: 238-878-4 CAS: 14808-60-7	≥1.0 - ≤5.0	STOT RE 1, H372 (inhalation)	-	[1] [2]
isobutyl acetate	EC: 203-745-1 CAS: 110-19-0 Index: 607-026-00-7	≥1.0 - ≤5.0	Flam. Liq. 2, H225 EUH066	-	[1] [2]
ethylbenzene	REACH #: 01-2119489370-35 EC: 202-849-4 CAS: 100-41-4 Index: 601-023-00-4	≥1.0 - ≤4.7	Flam. Liq. 2, H225 Acute Tox. 4, H332 STOT RE 2, H373 (hearing organs) Asp. Tox. 1, H304 Aquatic Chronic 3, H412	ATE [Inhalation (vapours)] = 17.8 mg/l	[1] [2]
Octadecanoic acid,	REACH #:	≤0.30	Skin Sens. 1B, H317	-	[1]
English (GB)			Europe		3/19

Code : 00000119 FREITAPOX SR 213 EVC		Date of issue/Date of revision	: 15 March 2024		
	ECTION 3: Composition/information on ingredients				
12-hydroxy-, reaction products with ethylenediamine	01-2119979085-27 EC: 309-629-8 CAS: 100545-48-0	Aquatic Chronic 3, H412			
		See Section 16 for the full text of the H statements declared above.			

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

<u>Type</u>

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

SUB codes represent substances without registered CAS Numbers.

### **SECTION 4: First aid measures**

#### 4.1 Description of first aid measures

Eye contact	: Remove contact lenses, irrigate copiously with clean, fresh water, holding the eyelids apart for at least 10 minutes and seek immediate medical advice.
Inhalation	: Remove to fresh air. Keep person warm and at rest. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel.
Skin contact	: Remove contaminated clothing and shoes. Wash skin thoroughly with soap and water or use recognised skin cleanser. Do NOT use solvents or thinners.
Ingestion	: If swallowed, seek medical advice immediately and show the container or label. Keep person warm and at rest. Do NOT induce vomiting.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

#### 4.2 Most important symptoms and effects, both acute and delayed

Potential acute health effec	<u>ts</u>
Eye contact	: Causes serious eye irritation.
Inhalation	: No known significant effects or critical hazards.
Skin contact	: Causes skin irritation. Defatting to the skin. May cause an allergic skin reaction.
Ingestion	: No known significant effects or critical hazards.
Over-exposure signs/sympt	toms
Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: No specific data.
Skin contact	: Adverse symptoms may include the following: irritation redness dryness cracking
Ingestion	: No specific data.

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878			
<mark>Code</mark> FREITAPO	: 000001199136 ( SR 213 EVO BASE GREY	Date of issue/Date of revision	: 15 March 2024

## **SECTION 4: First aid measures**

4.3 Indication of any immediate medical attention and special treatment needed			
Notes to physician	<ul> <li>Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.</li> </ul>		
Specific treatments	: No specific treatment.		

# **SECTION 5: Firefighting measures**

-	-
5.1 Extinguishing media	
Suitable extinguishing media	: Use dry chemical, CO <sub>2</sub> , water spray (fog) or foam.
Unsuitable extinguishing media	: Do not use water jet.
5.2 Special hazards arising f	om the substance or mixture
Hazards from the substance or mixture	: Highly flammable liquid and vapour. Runoff to sewer may create fire or explosion hazard. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. This material is harmful to aquatic life with long lasting effects. Fire water contaminated with this material must be contained and prevented from being discharged to any waterway, sewer or drain.
Hazardous combustion products	: Decomposition products may include the following materials: carbon oxides halogenated compounds metal oxide/oxides
5.3 Advice for firefighters	
Special precautions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

## **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.

#### 6.3 Methods and material for containment and cleaning up

English (GB) Europe 5/1	5/19
-------------------------	------

2020/070			
Code : 000 FREITAPOX SR 213	001199136 3 EVO BASE GREY	Date of issue/Date of revision	: 15 March 2024
<b>SECTION 6:</b> A	Accidental release n	neasures	
Small spill	explosion-proc or if water-inso	thout risk. Move containers from spill are of equipment. Dilute with water and mop oluble, absorb with an inert dry material a ainer. Dispose of via a licensed waste dis	up if water-soluble. Alternatively, nd place in an appropriate waste
Large spill	explosion-prod sewers, water treatment plan combustible, a place in conta	thout risk. Move containers from spill are of equipment. Approach the release from courses, basements or confined areas. It or proceed as follows. Contain and coll absorbent material e.g. sand, earth, verminer iner for disposal according to local regula al contractor. Contaminated absorbent material spilt product.	upwind. Prevent entry into Wash spillages into an effluent lect spillage with non- iculite or diatomaceous earth and tions. Dispose of via a licensed
6.4 Reference to ot sections	See Section 8	for emergency contact information. for information on appropriate personal p 3 for additional waste treatment informati	

## **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
7.2 Conditions for safe storage, including any incompatibilities	: Store between the following temperatures: 0 to 35°C (32 to 95°F). Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

#### 7.3 Specific end use(s)

See Section 1.2 for Identified uses.

Code : 000001199136 Date o

Date of issue/Date of revision

: 15 March 2024

FREITAPOX SR 213 EVO BASE GREY

### SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 8.1 Control parameters

#### **Occupational exposure limits**

Product/ingredient name	Exposure limit values
<b>xy</b> lene	EU OEL (Europe, 1/2022). [xylene, mixed isomers pure] Absorbed through skin. STEL: 442 mg/m <sup>3</sup> 15 minutes. STEL: 100 ppm 15 minutes. TWA: 221 mg/m <sup>3</sup> 8 hours.
o-xylene	TWA: 50 ppm 8 hours. <b>EU OEL (Europe, 1/2022). Absorbed through skin.</b> STEL: 442 mg/m <sup>3</sup> 15 minutes. STEL: 100 ppm 15 minutes. TWA: 221 mg/m <sup>3</sup> 8 hours.
butanone	TWA: 50 ppm 8 hours. <b>EU OEL (Europe, 1/2022).</b> STEL: 900 mg/m <sup>3</sup> 15 minutes. STEL: 300 ppm 15 minutes. TWA: 600 mg/m <sup>3</sup> 8 hours. TWA: 200 ppm 8 hours.
crystalline silica, respirable powder (<10 microns)	
isobutyl acetate	EU OEL (Europe, 1/2022). STEL: 150 ppm 15 minutes. STEL: 723 mg/m <sup>3</sup> 15 minutes. TWA: 241 mg/m <sup>3</sup> 8 hours. TWA: 50 ppm 8 hours.
ethylbenzene	EU OEL (Europe, 1/2022). Absorbed through skin. STEL: 884 mg/m <sup>3</sup> 15 minutes. STEL: 200 ppm 15 minutes. TWA: 442 mg/m <sup>3</sup> 8 hours. TWA: 100 ppm 8 hours.
procedures Standard EN 689	d be made to monitoring standards, such as the following: European (Workplace atmospheres - Guidance for the assessment of exposure hemical agents for comparison with limit values and measurement

Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

#### **DNELs**

Product/ingredient name	Туре	Exposure	Value	Population	Effects
<b>Ky</b> lene	DNEL DNEL DNEL DNEL DNEL DNEL DNEL	Long term Oral Long term Inhalation Long term Inhalation Long term Dermal Long term Dermal Long term Inhalation Short term Inhalation	12.5 mg/kg bw/day 65.3 mg/m <sup>3</sup> 65.3 mg/m <sup>3</sup> 125 mg/kg bw/day 212 mg/kg bw/day 221 mg/m <sup>3</sup> 221 mg/m <sup>3</sup> 260 mg/m <sup>3</sup>	General population General population General population General population Workers Workers Workers General population	Local Systemic Systemic Systemic Local Systemic
English (GB)			Europe		7/19

Code : 000001199136 FREITAPOX SR 213 EVO BASE GREY Date of issue/Date of revision

: 15 March 2024

**SECTION 8: Exposure controls/personal protection** 

Ox.YeleneDNELShort term inhalation DNEL200 mg/m² 442 mg/m² WorkersGeneral population Systemic General population Cal WorkersSystemic Local Workerso-xyleneDNELLong term Oral DNEL2.5 mg/kg bw/day UsersGeneral population General population Systemic General population Systemic General populationSystemic General population Systemic General population Systemic General population Systemic General population Systemic Center Inhalation DNELLong term Inhalation 221 mg/m² WorkersSystemic General population Systemic Center Inhalation 220 mg/m² General population Systemic Center Inhalation DNELSystemic Center Inhalation 280 mg/m² General population Systemic General population Systemic Center Inhalation DNELSystemic Center Inhalation 280 mg/m² General population Systemic General population Systemic General population Systemic General population Systemic General population Systemic General population Systemic General population Systemic Honkers Systemic Honkers Systemic Honkers DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation HONKEL Long term Inhalation DNEL Long term Cral DNEL Long term Inhalation DNEL Long term Cral DNEL Long term Inhalation DNEL Lon	SECTION 6. Exposure		iois/personal pro	lection		
DNEL         Short term inhalation         442 mg/m³         Workers         Local           DNEL         Long term Orai         25 mg/kg bw/day         General population         Systemic           DNEL         Long term Inhalation         65.3 mg/m³         General population         Systemic           DNEL         Long term Inhalation         125 mg/kg bw/day         General population         Systemic           DNEL         Long term Inhalation         221 mg/m³         Workers         Systemic           DNEL         Long term Inhalation         221 mg/m³         Workers         Systemic           DNEL         Long term Inhalation         220 mg/m³         Workers         Systemic           DNEL         Systemic         200 mg/m³         General population         Systemic           DNEL         Systemic         200 mg/m³         General population         Systemic           DNEL         Systemic         31 mg/kg bw/day         General population         Systemic           DNEL         Long term Inhalation         142 mg/m³         Workers         Systemic           DNEL         Long term Inhalation         12.5 mg/kg bw/day         General population         Systemic           DNEL         Long term Inhalation         12.2 mg/m³		DNEL	Short term Inhalation	260 mg/m <sup>3</sup>	General population	Systemic
DNEL         Short term inhalation         442 mg/m³         Workers         Systemic           DNEL         Long term / naiter         65.3 mg/m³         General population         Systemic           DNEL         Long term / naiter         65.3 mg/m³         General population         Systemic           DNEL         Long term / naiter         65.3 mg/m³         General population         Systemic           DNEL         Long term / naiter         125 mg/kg bw/day         General population         Systemic           DNEL         Long term / naiter         221 mg/m³         Workers         Local           DNEL         Systemic         221 mg/m³         Workers         Local           DNEL         Short term inhalation         242 mg/m³         Workers         Local           DNEL         Short term inhalation         260 mg/m³         General population         Systemic           DNEL         Long term / naitation         142 mg/m³         Workers         Systemic           DNEL         Long term / naitation         106 mg/m³         General population         Systemic           DNEL         Long term / naitation         12.25 mg/kg bw/day         General population         Systemic           DNEL         Long term / naitation         12.25 m				0		
o-xylene         DNEL         Long term Oral         2.5 mg/kg bw/day         General population         Systemic           DNEL         Long term Inhalation         65.3 mg/m³         General population         Systemic           DNEL         Long term Dermal         125 mg/kg bw/day         General population         Systemic           DNEL         Long term Inhalation         221 mg/m³         Workers         Systemic           DNEL         Long term Inhalation         221 mg/m³         Workers         Systemic           DNEL         Short term Inhalation         220 mg/m³         Workers         Systemic           DNEL         Short term Inhalation         242 mg/m³         Workers         Systemic           DNEL         Short term Inhalation         442 mg/m³         Workers         Systemic           DNEL         Long term Ornal         31 mg/kg bw/day         General population         Systemic           DNEL         Long term Inhalation         125 mg/kg bw/day         General population         Systemic           DNEL         Long term Dermal         31 mg/kg bw/day         General population         Systemic           DNEL         Short term Inhalation         122 mg/m³         Workers         Systemic           DNEL         Long t						
DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL	o-xylene					
butanone         DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL	o xylone					
DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Short term inhalation DNEL Short term inhalation DNEL Short term inhalation DNEL Short term inhalation DNEL Short term inhalation DNEL Short term inhalation DNEL 						
DNEL         Long term Inhalation         212 mg/kg bw/day         Workers         Systemic           DNEL         Long term Inhalation         221 mg/m <sup>2</sup> Workers         Systemic           DNEL         Short term Inhalation         220 mg/m <sup>2</sup> General population         Systemic           DNEL         Short term Inhalation         420 mg/m <sup>2</sup> General population         Systemic           DNEL         Short term Inhalation         442 mg/m <sup>2</sup> Workers         Systemic           DNEL         Short term Inhalation         106 mg/m <sup>2</sup> General population         Systemic           DNEL         Long term Inhalation         DNEL         General population         Systemic           DNEL         Long term Inhalation         DNEL         General population         Systemic           DNEL         Long term Inhalation         DNEL         Gong/m <sup>2</sup> Workers         Systemic           DNEL         Long term Dermal         1161 mg/kg bw/day         Workers         Systemic           DNEL         Short term Inhalation         12.25 mg/m <sup>2</sup> Workers         Systemic           DNEL         Long term Dermal         8.33 mg/kg bw/day         Workers         Systemic           DNEL         Long term Dermal						
DNEL DNEL DNEL DNEL DNEL DNEL DNEL Short term inhalation DNEL Short term inhalation DNEL Short term inhalation DNEL Short term inhalation DNEL 						
DNEL butanoneDNEL DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term Oral DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Oral12.25 mg/m3 Norkers Norkers Systemic Workers Systemic Workers Systemic Systemic Systemic Systemic Systemic DNEL DNEL Long term Oral0.75 mg/kg bw/day Consumers] General Systemic Systemic Systemic Systemic Systemic DNEL Long term Oral0.75 mg/kg bw/day General Systemic Systemic Systemic Systemic Systemic Systemic Systemic DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNE						
butanoneDNEL DNEL Short term Inhalation DNEL Short term Inhalation DNEL Short term Inhalation DNEL DNEL DNEL DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Oral12.25 mg/m² Norkers Systemic Workers Systemic Workers Systemic Workers Systemic Systemic DNEL Consumers] General General Systemic Systemic DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation <br< th=""><td></td><td></td><td></td><td></td><td></td><td></td></br<>						
butanoneDNEL DNELShort term Inhalation DNEL260 mg/m² ygtemic WorkersGeneral population Systemic General population Systemic Workers Workers Systemic Workers Systemic Workers Systemicbis-[4-(2.3-epoxipropoxi)DNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term OralWorkers Systemic Workers Systemic Workers Systemic Workers Systemic Systemic General population [Consumers] General Systemic population [Consumers] General Systemic population [Consumers] General Systemic Systemic Systemic population [Consumers] General Systemic Systemic Systemic Systemic Systemic Systemic General Systemic Systemic General Systemic Systemic General Systemic General Systemic General Systemic General Systemic General Systemic General Systemic General Systemic General Systemic General Systemic General Systemic General Systemic General Systemic General S						
butanoneDNEL DNEL Short term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal Systemic Systemic Systemic Systemic Workers Systemic Workers Systemic Workers Systemic<						
butanoneDNEL DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL DNEL Long term Dermal DNEL D						-
butanoneDNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Oral12.25 mg/m³ Workers Systemic Workers Systemic Workers Consumers] General Systemic population [Consumers] General Systemic population [Consumers] General population Systemic population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Systemic Morkers Systemic Systemic Morkers Systemic DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Drahalation DNEL Long term Drahalation DNEL Long term Inhalation DNEL Long term Inhalat						
Isobutyl acetateDNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL 						
DNEL DNEL DNEL bis-[4-(2,3-epoxipropoxi)DNEL DNEL Short term Inhalation DNEL <td>butanone</td> <td></td> <td>Long term Oral</td> <td>31 mg/kg bw/day</td> <td>General population</td> <td>Systemic</td>	butanone		Long term Oral	31 mg/kg bw/day	General population	Systemic
DNEL bis-[4-(2.3-epoxipropoxi) phenyl]propaneDNEL DNEL 		DNEL	Long term Inhalation	106 mg/m³	General population	Systemic
DNEL bis-[4-(2,3-epoxipropoxi) phenyl]propaneDNEL <b< th=""><td></td><td>DNEL</td><td>Long term Dermal</td><td>412 mg/kg bw/day</td><td>General population</td><td>Systemic</td></b<>		DNEL	Long term Dermal	412 mg/kg bw/day	General population	Systemic
DNEL bis-[4-(2,3-epoxipropoxi) phenyl]propaneDNEL DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL DNEL DNEL Long term Dermal DNEL DNEL DNEL Long term Dermal DNEL DNEL DNEL Long term Dermal DNEL DNEL DNEL Long term Dermal DNEL <br< th=""><td></td><td>DNEL</td><td>Short term Inhalation</td><td>450 mg/m<sup>3</sup></td><td>General population</td><td>Systemic</td></br<>		DNEL	Short term Inhalation	450 mg/m <sup>3</sup>	General population	Systemic
bis-[4-(2,3-epoxipropoxi) phenyl]propaneDNEL DNEL DNEL DNELShort term Inhalation Long term Inhalation DNEL DNEL900 mg/m³ 1161 mg/kg bw/day 12.25 mg/m³ 8.33 mg/kg bw/day 8.33 mg/kg bw/day 8.3571 mg/kg bw/dayWorkers Workers Systemic Workers Systemic Systemic Norkers Systemic population [Consumers]] General population [Consumers]]Systemic Systemic Systemic Systemic population [Consumers]]Isobutyl acetateDNEL DNELShort term Oral DNEL0.75 mg/kg bw/day 0.75 mg/kg bw/dayWorkers Workers Systemic population [Consumers]]Systemic Systemic population [Consumers]]Isobutyl acetateDNEL DNELLong term Dermal DNEL DNEL0.75 mg/kg bw/day 0.75 mg/kg bw/day 0.75 mg/kg bw/dayGeneral General General population [Consumers]]Systemic Systemic Systemic Systemic Systemic Systemic Systemic Systemic Systemic 0.5 mg/kg bw/daySystemic Syst				0		
bis-[4-(2,3-epoxipropoxi) phenyl]propaneDNEL DNEL DNELLong term Inhalation DNEL DNEL DNEL1161 mg/kg bw/day 12.25 mg/m³Workers WorkersSystemic SystemicDNEL DNEL DNEL DNELShort term Inhalation DNEL DNEL DNEL12.25 mg/m³ 8.33 mg/kg bw/day 3.571 mg/kg bw/day 3.571 mg/kg bw/dayWorkers Workers Systemic General population [Consumers] General population [Consumers]Systemic Systemic Systemic Bystemic SystemicDNEL DNELShort term Dermal DNEL3.571 mg/kg bw/day 3.571 mg/kg bw/dayWorkers Workers Systemic General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population [Consumers] General population Systemic Sys						
bis-I4-(2.3-epoxipropoxi) phenyl]propaneDNEL DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Oral12.25 mg/m³ m3/kg bw/day B.33 mg/kg bw/day S.571 mg/kg bw/day General Opulation (Consumers) General population (Consumers) General population (Consumers) General population (Consumers) General population (Consumers) General population (Consumers) General population (Consumers) General population (Consumers) General population (Consumers) General population (Consumers) General population (Consumers) General population (Consumers) General population Systemic Systemi				0		
phenyljpropaneNNNDNEL DNEL DNEL DNEL DNEL DNELShort term Inhalation Long term Dermal DNEL Long term Dermal12.25 mg/m³ 8.33 mg/kg bw/day 3.571 mg/kg bw/dayWorkers Workers General opulation [Consumers] General general population [Consumers] General general DNEL DNELShort term Dermal DNEL12.25 mg/m³ 8.33 mg/kg bw/day S.571 mg/kg bw/dayWorkers Workers Workers Systemic population [Consumers] General population [Consumers] General population [Consumers] General Downers] General Downers] General Downers] General Downers] General Downers] General Downers] General Downers] General Downers] General population Systemic Sys	bis-[4-(2,3-epoxipropoxi)					
DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNELShort term Dermal Long term Dermal Long term Dermal DNEL DNEL DNEL DNELShort term Dermal DNEL Long term Dermal12.25 mg/m3 B.33 mg/kg bw/day B.33 mg/kg bw/day B.33 mg/kg bw/day S.571 mg/kg bw/dayWorkers Workers General population [Consumers] General population [Consumers]Systemic Systemic population [Consumers]DNEL DNELShort term Oral0.75 mg/kg bw/dayGeneral General population [Consumers]Systemic Systemic population [Consumers]DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term Oral0.75 mg/kg bw/day 0.75 mg/kg bw/dayGeneral General General population [Consumers]Systemic Systemic Systemic General population Systemic 0.5 mg/kg bw/dayIsobutyl acetateDNEL Long term Inhalation DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL DNEL Long term Oral DNEL Short term Dermal DNEL Long term Inhalation DNEL Long term						,
DNEL DNEL DNEL DNELLong term Dermal Short term Dermal Long term Dermal8.33 mg/kg bw/day 8.33 mg/kg bw/dayWorkers WorkersSystemic SystemicDNEL DNELLong term Dermal3.571 mg/kg bw/dayGeneral population [Consumers] General population [Consumers]]Systemic SystemicDNEL DNELShort term Dermal3.571 mg/kg bw/dayGeneral population [Consumers]]Systemic systemic population [Consumers]]DNEL DNELLong term Oral0.75 mg/kg bw/day 0.75 mg/kg bw/dayGeneral population [Consumers]]Systemic systemic population [Consumers]]DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL Short term Oral89.3 µg/kg bw/day 0.75 mg/kg bw/day 0.75 mg/kg bw/day 0.75 mg/kg bw/day General population General population Systemic General population Systemic Systemic General population Systemic General population Syst	h	DNFI	Short term Inhalation	12 25 mg/m <sup>3</sup>	Workers	Systemic
DNEL DNELShort term Dermal Long term Dermal8.33 mg/kg bw/day 3.571 mg/kg bw/dayWorkers General population [Consumers] General population [Consumers]Systemic SystemicDNEL DNELShort term Dermal3.571 mg/kg bw/dayWorkersSystemic gopulation [Consumers]DNEL DNELLong term Oral0.75 mg/kg bw/dayGeneral population [Consumers]Systemic gopulation [Consumers]DNEL DNELLong term Oral0.75 mg/kg bw/dayGeneral population [Consumers]Systemic SystemicDNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term Dermal DNEL Long term Inhalation DNEL DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL Long term Oral DNEL DNEL DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL Long term Oral DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term Oral DNEL						
DNELLong term Dermal3.571 mg/kg bw/dayGeneral population [Consumers] General population [Consumers]]SystemicDNELShort term Dermal3.571 mg/kg bw/dayGeneral General population [Consumers]]SystemicDNELLong term Oral0.75 mg/kg bw/dayGeneral General population [Consumers]]SystemicDNELLong term Oral0.75 mg/kg bw/dayGeneral General population [Consumers]]SystemicDNELLong term Oral0.75 mg/kg bw/dayGeneral population General population [Consumers]]Systemic SystemicDNELLong term Dermal DNELLong term Inhalation DNELSoft term Inhalation 300 mg/m3General population General population Systemic SystemicSystemic Systemic Systemic Systemicisobutyl acetateDNEL DNELShort term Oral DNELS mg/kg bw/day General population SystemicSystemic Systemicisobutyl acetateDNEL DNELShort term Oral DNELS mg/kg bw/day General population SystemicSystemic SystemicDNEL DNELShort term Oral DNELS mg/kg bw/day General population SystemicSystemic SystemicDNEL DNEL DNELLong term Dermal DNELSmg/kg bw/day General populationSystemic SystemicDNEL DNEL DNEL DNELShort term Inhalation DNELStort term Inhalation 300 mg/m3General population General population General population SystemicDNEL DNEL DNEL DNEL DNEL DNEL DNELShort term Inhalatio						
Image: solution of the second secon						
DNELShort term Dermal3.571 mg/kg bw/day[Consumers] General population [Consumers]Systemic SystemicDNELLong term Oral0.75 mg/kg bw/dayGeneral General population [Consumers]Systemic SystemicDNELShort term Oral0.75 mg/kg bw/dayGeneral General population (Consumers]Systemic SystemicDNELLong term Dermal DNEL0.75 mg/kg bw/dayGeneral population (General population Systemic Onto m (Consumers]Systemic SystemicDNELLong term Dermal DNEL0.75 mg/kg bw/dayGeneral population (Seneral population Systemic Systemic Systemic SystemicDNELLong term Inhalation DNEL0.75 mg/kg bw/dayGeneral population Systemic Systemic Systemic SystemicIsobutyl acetateDNELShort term Inhalation DNEL0.87 mg/m³ S mg/kg bw/dayGeneral population Systemic Systemic Systemic SystemicIsobutyl acetateDNELShort term Oral DNEL5 mg/kg bw/day Sort term Inhalation DNEL5 mg/kg bw/day Sort term Dermal Sort term DermalSystemic Systemic SystemicDNELLong term Inhalation DNEL10 mg/kg bw/day Sort term Inhalation DNELSystemic SystemicSystemic SystemicDNELLong term Inhalation DNEL35.7 mg/m³ General population Sort term Inhalation DNELSort term Inhalation Sort minhalation DNELSort term Inhalation Sort minhalation DNELSort term Inhalation Sort minhalation Sort term Inhalation DNELSort term Inhalation Sort min			Long term Derma	5.57 Ting/kg bw/day		Oysternic
DNELShort term Dermal3.571 mg/kg bw/dayGeneral population [Consumers] General population [Consumers]SystemicDNELLong term Oral0.75 mg/kg bw/dayGeneral population [Consumers]SystemicDNELShort term Oral0.75 mg/kg bw/dayGeneral population [Consumers]SystemicDNELLong term Dermal DNEL0.75 mg/kg bw/dayGeneral oppulation (Consumers]SystemicDNELLong term Dermal DNEL0.75 mg/kg bw/dayGeneral oppulation (Consumers]SystemicDNELLong term Dermal DNEL0.75 mg/kg bw/dayGeneral oppulation (General oppulation SystemicSystemicDNELLong term Inhalation DNEL0.87 mg/m3Workers General oppulationSystemicDNELShort term Oral DNELSmg/kg bw/dayGeneral population General populationSystemicDNELShort term Oral DNELSmg/kg bw/dayGeneral population General populationSystemicDNELShort term Oral DNELSmg/kg bw/dayGeneral population General populationSystemicDNELLong term Dermal DNEL10 mg/kg bw/dayGeneral population General populationSystemicDNELLong term Inhalation DNEL35.7 mg/m3General population General populationSystemicDNELLong term Inhalation DNEL300 mg/m3General population General populationSystemicDNELLong term Inhalation DNEL300 mg/m3General population General populationSystem						
Image: DNELLong term Oral0.75 mg/kg bw/daypopulation [Consumers] General population [Consumers]Systemic population [Consumers]DNELShort term Oral0.75 mg/kg bw/dayGeneral general population [Consumers]Systemic population [Consumers]DNELLong term Dermal DNELLong term Dermal DNEL0.75 mg/kg bw/dayGeneral general population SystemicDNELLong term Dermal DNELLong term Dermal DNEL0.75 mg/kg bw/dayGeneral population General population SystemicDNELLong term Inhalation DNELShort term Inhalation DNEL0.87 mg/m3 SigtemicGeneral population SystemicDNELShort term Inhalation DNELShort term Dermal DNELSmg/kg bw/day SigtemicGeneral population SystemicDNELShort term Oral DNELSmg/kg bw/day SigtemicGeneral population SystemicSystemic SystemicDNELShort term Dermal DNELSmg/kg bw/day SigtemicGeneral population SystemicSystemic SystemicDNELLong term Dermal DNELSmg/kg bw/day SigtemicGeneral population SystemicSystemic SystemicDNELLong term Inhalation DNELShort term Inhalation DNEL300 mg/m3 SigtemicGeneral population SystemicDNELLong term Inhalation DNELShort term Inhalation DNEL300 mg/m3 SigtemicGeneral population SystemicDNELLong term Inhalation DNELShort term Inhalation DNEL300 mg/m3 SigtemicGeneral popula			Short torm Dormal	2 571 ma/ka bw/day		Svetomie
DNELLong term Oral0.75 mg/kg bw/day[Consumers] General population [Consumers]Systemic population [Consumers]DNELShort term Oral0.75 mg/kg bw/dayGeneral opulation [Consumers]Systemic SystemicDNELLong term Dermal DNELLong term Oral0.75 mg/kg bw/dayGeneral population General population (Consumers]Systemic SystemicDNELLong term Oral0.75 mg/kg bw/dayGeneral population SystemicSystemic SystemicDNELLong term Inhalation DNEL0.87 mg/m3General population SystemicSystemic SystemicDNELShort term Inhalation DNELShort term OralSmg/kg bw/day Smg/kg bw/dayGeneral population SystemicSystemic SystemicDNELShort term OralSmg/kg bw/day Smg/kg bw/dayGeneral population SystemicSystemic SystemicDNELShort term Dermal DNELShort term Dermal DNELSmg/kg bw/day Seneral populationSystemic SystemicDNELShort term Dermal DNELShort term Dermal DNELSmg/kg bw/day Seneral populationSystemic SystemicDNELLong term Inhalation DNELShort term Inhalation DNEL300 mg/m3 Sor mg/m3General population General populationDNELShort term Inhalation DNELShort term Inhalation DNEL300 mg/m3 Sor mg/m3General population General population LocalDNELShort term Inhalation DNELShort term Inhalation DNELShort term Inhalation Som g/m3Sor mg/m3 Sor		DNEL	Short term Derma	5.57 Ting/kg bw/uay		Systemic
DNELLong term Oral0.75 mg/kg bw/dayGeneral population [Consumers]SystemicDNELShort term Oral0.75 mg/kg bw/dayGeneral population [Consumers]SystemicDNELLong term Dermal DNELLong term Oral0.75 mg/kg bw/dayGeneral population general populationSystemicDNELLong term Oral DNELLong term Oral0.75 mg/kg bw/dayGeneral population general populationSystemicDNELLong term Inhalation DNELShort term Inhalation0.87 mg/m³General population general populationSystemic SystemicDNELShort term Inhalation DNELShort term Oral5 mg/kg bw/dayGeneral population General populationSystemic SystemicDNELShort term Oral5 mg/kg bw/dayGeneral population General populationSystemic SystemicDNELLong term Dermal5 mg/kg bw/dayGeneral population General populationSystemic SystemicDNELLong term Dermal5 mg/kg bw/dayGeneral population General populationSystemic SystemicDNELLong term Dermal10 mg/kg bw/dayGeneral population General populationSystemic SystemicDNELLong term Inhalation35.7 mg/m³ General populationGeneral population SystemicSystemic LocalDNELLong term Inhalation300 mg/m³ General populationGeneral population SystemicSystemicDNELLong term Inhalation300 mg/m³ General populationGeneral population LocalSystemic <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
DNEL isobutyl acetateDNEL DNEL Long term OralShort term Oral0.75 mg/kg bw/daypopulation [Consumers] General population [Consumers]Systemic Systemic Systemicisobutyl acetateDNEL DNEL Long term Oral DNEL DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long te			Long torm Oral	0.75 mg/kg bw/dov		Sustamia
DNELShort term Oral0.75 mg/kg bw/day[Consumers] General population [Consumers]SystemicDNELLong term Dermal89.3 µg/kg bw/dayGeneral population (General population Distribution) DNEL Long term InhalationNerverseSystemic Systemicisobutyl acetateDNELLong term Inhalation DNEL Long term Inhalation0.87 mg/kg bw/day Ong term InhalationGeneral population SystemicSystemic Systemicisobutyl acetateDNEL DNEL Long term Inhalation0.87 mg/kg bw/day SystemicGeneral population SystemicSystemic SystemicDNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL Long term InhalationSmg/kg bw/day Smg/kg bw/dayGeneral population SystemicSystemic SystemicDNEL DNEL DNEL Long term DermalSmg/kg bw/day Smg/kg bw/dayGeneral population SystemicSystemic SystemicDNEL DNEL Long term DermalSmg/kg bw/day Smg/kg bw/dayGeneral population SystemicSystemic SystemicDNEL DNEL Long term Inhalation DNEL Long term Inhalation35.7 mg/m³ General population SystemicGeneral population SystemicSystemic Local LocalDNEL DNEL Long term Inhalation DNEL Long		DNEL	Long term Oral	0.75 mg/kg bw/day		Systemic
DNELShort term Oral0.75 mg/kg bw/dayGeneral population [Consumers]SystemicDNELLong term Dermal89.3 µg/kg bw/dayGeneral population [Consumers]SystemicDNELLong term Oral0.5 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.75 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation0.87 mg/m³General populationSystemicDNELLong term Inhalation0.87 mg/m³General populationSystemicDNELShort term Oral5 mg/kg bw/dayGeneral populationSystemicDNELShort term Oral5 mg/kg bw/dayGeneral populationSystemicDNELShort term Oral5 mg/kg bw/dayGeneral populationSystemicDNELShort term Dermal5 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal5 mg/kg bw/dayGeneral populationSystemicDNELLong term Dermal10 mg/kg bw/dayGeneral populationSystemicDNELLong term Inhalation35.7 mg/m³General populationSystemicDNELLong term Inhalation300 mg/m³General populationSystemicDNELLong term Inhalation300 mg/m³WorkersSystemicDNELLong term Inhalation300 mg/m³WorkersSystemicDNELLong term Inhalation300 mg/m³WorkersLocalDNELShort term Inhalation300 mg/m³WorkersSystemic						
DNEL Isobutyl acetateLong term Dermal Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Oral DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term In			Chartterne Oral			0
Isobutyl acetateDNEL DNEL Long term Oral Long term Oral DNEL Long term Inhalation DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Oral DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhalation DNEL		DNEL	Short term Oral	0.75 mg/kg bw/day		Systemic
DNEL DNEL DNEL Long term Oral DNEL DNEL Long term Oral DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Oral DNEL Short term Oral DNEL Short term Oral DNEL DNEL Long term Inhalation DNEL Short term Oral DNEL Short term Oral DNEL DNEL DNEL Long term Inhalation DNEL DNEL DNEL DNEL Long term Inhalation DNEL DNEL Long term Oral DNEL Short term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL DNEL Long term Dermal DNEL Long term Dermal DNEL Long term Inhalation DNEL Long term Inhalation DNEL Short term Inhal						
DNEL DNEL DNEL DNELLong term Oral Long term Inhalation DNEL DNEL0.5 mg/kg bw/day DNEL						<b>a</b>
DNEL isobutyl acetateDNEL DNEL DNEL DNELLong term Inhalation DNEL DNEL DNEL0.75 mg/kg bw/day 0.87 mg/m3Workers General population Systemic Systemic SystemicSystemic Systemic Systemicisobutyl acetateDNEL DNE						
DNEL isobutyl acetateDNEL DNEL DNELLong term Inhalation DNEL Short term Inhalation DNEL0.87 mg/m³ 4.93 mg/m³ 300 mg/m³General population Systemic General population Systemic General populationSystemic Systemic Systemicisobutyl acetateDNEL DNELShort term Oral DNELShort term Oral DNEL5 mg/kg bw/day S mg/kg bw/dayGeneral population General populationSystemic SystemicDNEL DNELCong term Oral DNELShort term Dermal DNEL5 mg/kg bw/day SystemicGeneral population SystemicSystemic SystemicDNEL DNELCong term Dermal DNELShort term Dermal DNEL10 mg/kg bw/day SystemicGeneral population SystemicSystemic SystemicDNEL DNELLong term Inhalation DNELLong term Inhalation DNEL35.7 mg/m³ General populationGeneral population SystemicSystemic LocalDNEL DNELLong term Inhalation DNEL300 mg/m³ General populationGeneral population LocalLocal LocalDNEL DNEL DNELShort term Inhalation DNEL300 mg/m³ Gon mg/m³Workers WorkersLocal LocalDNEL DNEL DNEL DNELShort term Inhalation DNEL300 mg/m³ Gon mg/m³Workers WorkersLocal SystemicDNEL DNEL DNELShort term Inhalation DNELShort term Inhalation Gon mg/m³Gon mg/m³ WorkersWorkers SystemicLocal SystemicDNEL DNELShort term Inhalation DNELShort term Inhalation Gon mg/m³ <td< th=""><td></td><td></td><td></td><td></td><td></td><td></td></td<>						
Isobutyl acetateDNEL DNEL DNELLong term Inhalation Short term Inhalation DNEL DNEL4.93 mg/m³ S00 mg/m³WorkersSystemic Systemicisobutyl acetateDNEL <b< th=""><td></td><td></td><td></td><td></td><td></td><td></td></b<>						
isobutyl acetateDNEL DNELShort term Inhalation DNEL300 mg/m³ 5 mg/kg bw/day 5 mg/kg bw/day 5 mg/kg bw/day 6 General population General population Systemic Systemic Systemic Systemic Systemicisobutyl acetateDNEL DNELShort term Oral DNEL DNELShort term Oral DNEL DNELShort term Dermal DNEL DNELShort term Dermal DNEL DNELShort term Dermal DNEL DNELShort term Dermal DNELSmg/kg bw/day SystemicGeneral population Systemic SystemicSystemic SystemicDNEL DNEL DNELCong term Dermal DNEL DNELLong term Dermal DNEL DNEL10 mg/kg bw/day SystemicWorkers SystemicSystemic SystemicDNEL DNEL DNELLong term Inhalation DNEL35.7 mg/m³ Sont term Inhalation Sond mg/m³General population Systemic Local SystemicLocal Local LocalDNEL DNEL DNELShort term Inhalation DNEL300 mg/m³ Sond mg/m³Workers WorkersSystemic Local Local LocalDNEL DNEL DNELShort term Inhalation DNEL300 mg/m³ Sond mg/m³Workers WorkersSystemic Local LocalDNEL DNEL DNELShort term Inhalation DNEL300 mg/m³ Sont term InhalationWorkers Sond mg/m³Systemic Systemic			0		• •	
DNEL DNEL DNELShort term Oral Long term Oral5 mg/kg bw/day 5 mg/kg bw/dayGeneral population General populationSystemic SystemicDNEL DNELShort term Dermal DNEL5 mg/kg bw/day 5 mg/kg bw/dayGeneral population General populationSystemic SystemicDNEL DNELLong term Dermal DNEL10 mg/kg bw/day UNELWorkersSystemic SystemicDNEL DNELLong term Dermal DNEL10 mg/kg bw/day UNELWorkersSystemic SystemicDNEL DNEL DNELLong term Inhalation DNEL35.7 mg/m³ General populationGeneral population UNGKersLocal LocalDNEL DNELLong term Inhalation DNEL300 mg/m³ General populationSystemic LocalLocal LocalDNEL DNEL DNELLong term Inhalation DNEL300 mg/m³ General populationWorkers LocalLocal LocalDNEL DNEL DNELLong term Inhalation DNEL300 mg/m³ General populationWorkers LocalLocal LocalDNEL DNEL DNEL DNELShort term Inhalation Short term Inhalation Short term InhalationGeneral population General populationLocal LocalDNEL DNEL DNELShort term Inhalation Short term InhalationGeneral population General populationLocal LocalDNEL DNEL DNELShort term Inhalation Short term InhalationGeneral population General populationLocal LocalDNEL DNEL DNELShort term Inhalation Short term InhalationGeneral population General popu						
DNEL DNEL DNELLong term Oral Short term Dermal DNEL5 mg/kg bw/day Smg/kg bw/dayGeneral population General population General population SystemicSystemic SystemicDNEL DNELShort term Dermal DNELLong term Dermal DNEL10 mg/kg bw/day Ung term Inhalation DNEL10 mg/kg bw/day WorkersWorkers SystemicSystemic SystemicDNEL DNELLong term Inhalation DNELLong term Inhalation DNEL35.7 mg/m³ General populationGeneral population SystemicSystemic SystemicDNEL DNELLong term Inhalation DNELShort term Inhalation DNEL300 mg/m³ General populationSystemic LocalDNEL DNELLong term Inhalation DNELShort term Inhalation DNEL300 mg/m³ General populationSystemic LocalDNEL DNELShort term Inhalation DNELShort term Inhalation Short term Inhalation300 mg/m³ General populationWorkers SystemicLocal LocalDNEL DNELShort term Inhalation Short term Inhalation300 mg/m³ General populationSystemic LocalLocal Systemic	isobutyl acetate					
DNEL DNEL DNELShort term Dermal Long term Dermal DNEL5 mg/kg bw/day Smg/kg bw/dayGeneral population SystemicSystemic SystemicDNEL DNELShort term Dermal DNEL10 mg/kg bw/day 10 mg/kg bw/dayWorkers WorkersSystemic SystemicDNEL DNELLong term Dermal DNEL10 mg/kg bw/day 10 mg/kg bw/dayWorkers General populationSystemic SystemicDNEL DNELLong term Inhalation DNEL35.7 mg/m³ 300 mg/m³General population General populationLocal SystemicDNEL DNELShort term Inhalation DNEL300 mg/m³ 300 mg/m³Workers WorkersLocal LocalDNEL DNELLong term Inhalation DNEL300 mg/m³ 600 mg/m³Workers WorkersLocal SystemicDNEL DNELShort term Inhalation DNELShort term Inhalation Short term Inhalation300 mg/m³ 600 mg/m³Workers WorkersSystemic SystemicDNEL DNELShort term Inhalation Short term Inhalation600 mg/m³ 600 mg/m³Workers WorkersSystemic Systemic						
DNEL DNELLong term Dermal Short term Dermal5 mg/kg bw/day 10 mg/kg bw/dayGeneral population WorkersSystemic SystemicDNEL DNELLong term Dermal DNEL10 mg/kg bw/day 10 mg/kg bw/dayWorkersSystemic SystemicDNEL DNELLong term Inhalation DNEL35.7 mg/m³ 35.7 mg/m³General population General populationLocal LocalDNEL DNELLong term Inhalation DNEL35.7 mg/m³ 300 mg/m³General population General populationLocal LocalDNEL DNELLong term Inhalation DNEL300 mg/m³ 300 mg/m³Workers WorkersLocal LocalDNEL DNELLong term Inhalation DNEL300 mg/m³ 600 mg/m³Workers WorkersLocal SystemicDNEL DNEL DNELShort term Inhalation Short term Inhalation300 mg/m³ 600 mg/m³Workers WorkersSystemic Local Systemic				000		
DNEL DNEL DNEL DNELShort term Dermal Long term Dermal10 mg/kg bw/day 10 mg/kg bw/dayWorkersSystemic SystemicDNEL DNEL DNELLong term Inhalation DNEL35.7 mg/m³ 35.7 mg/m³General population General populationLocal SystemicDNEL DNELLong term Inhalation DNELShort term Inhalation DNEL300 mg/m³ 300 mg/m³General population UndersonLocal LocalDNEL DNELLong term Inhalation DNELShort term Inhalation BNEL300 mg/m³ 400 mg/m³Workers VorkersLocal LocalDNEL DNELLong term Inhalation BNELShort term Inhalation BNet300 mg/m³ 400 mg/m³Workers 400 mg/m³Local 400 mg/m³DNEL DNELShort term Inhalation BNetShort term Inhalation 600 mg/m³Workers 400 mg/m³Systemic 400 mg/m³			Short term Dermal		General population	Systemic
DNEL DNEL DNELShort term Dermal Long term Dermal DNEL10 mg/kg bw/day Long term Dermal 10 mg/kg bw/dayWorkers WorkersSystemic SystemicDNEL DNELLong term Inhalation DNEL35.7 mg/m³ 35.7 mg/m³General population General population General population UndersLocal LocalDNEL DNELShort term Inhalation DNEL300 mg/m³ 300 mg/m³Workers General population Local UndersLocal Local LocalDNEL DNELLong term Inhalation DNEL300 mg/m³ Gon mg/m³Workers WorkersLocal Local LocalDNEL DNELShort term Inhalation Short term Inhalation300 mg/m³ Gon mg/m³Workers WorkersLocal Local SystemicDNEL DNELShort term Inhalation Short term InhalationGon mg/m³ Gon mg/m³Workers WorkersSystemic Local Systemic		DNEL	Long term Dermal			
DNEL DNEL DNELLong term Dermal Long term Inhalation DNEL10 mg/kg bw/day S5.7 mg/m³Workers General population General population SystemicSystemic LocalDNEL DNELLong term Inhalation DNEL35.7 mg/m³ 300 mg/m³General population General population UNELSystemic LocalDNEL DNELShort term Inhalation DNEL300 mg/m³ 300 mg/m³Workers WorkersLocal Local LocalDNEL DNELLong term Inhalation DNEL300 mg/m³ General populationWorkers Local LocalLocal SystemicDNEL DNELShort term Inhalation Short term Inhalation300 mg/m³ Gon mg/m³Workers WorkersSystemic Local SystemicDNEL DNELShort term Inhalation Short term Inhalation600 mg/m³ Gon mg/m³Workers WorkersSystemic Local		DNEL	Short term Dermal	10 mg/kg bw/day	Workers	Systemic
DNEL DNEL DNELLong term Inhalation Long term Inhalation DNEL35.7 mg/m³ S.7 mg/m³ S.7 mg/m³General population General population General population Uncl DNELLocal Local Local Local DNELDNEL <td></td> <td>DNEL</td> <td>Long term Dermal</td> <td></td> <td>Workers</td> <td></td>		DNEL	Long term Dermal		Workers	
DNEL DNELLong term Inhalation Short term Inhalation35.7 mg/m³ 300 mg/m³General population 		DNEL			General population	
DNEL DNELShort term Inhalation Long term Inhalation300 mg/m³ 300 mg/m³General population VorkersLocal LocalDNEL DNELLong term Inhalation DNEL300 mg/m³ 300 mg/m³WorkersLocal SystemicDNEL DNELShort term Inhalation Short term Inhalation600 mg/m³ 600 mg/m³WorkersLocal SystemicDNEL DNELShort term Inhalation Short term Inhalation600 mg/m³ 600 mg/m³WorkersLocal Systemic						
DNEL DNEL DNELLong term Inhalation Long term Inhalation DNEL300 mg/m3 300 mg/m3Workers WorkersLocal Systemic LocalDNEL DNELShort term Inhalation Short term Inhalation600 mg/m3 600 mg/m3Workers WorkersLocal Systemic						
DNELLong term Inhalation300 mg/m³WorkersSystemicDNELShort term Inhalation600 mg/m³WorkersLocalDNELShort term Inhalation600 mg/m³WorkersSystemic						
DNEL DNELShort term Inhalation Short term Inhalation600 mg/m³ 600 mg/m³WorkersLocal Systemic						
DNEL         Short term Inhalation         600 mg/m³         Workers         Systemic						
English (GB) Europe 8/19				000 mg/m		- ,
English (GD) Europe 8/19	English (CD)	•		Europe		0/40
	English (GB)			Europe		0/19

Code: 000001199136Date of issue/Date of revisionFREITAPOX SR 213 EVO BASE GREY

: 15 March 2024

**SECTION 8: Exposure controls/personal protection** 

•		• •			
ethylbenzene	DMEL	Long term Inhalation	442 mg/m <sup>3</sup>	Workers	Local
	DMEL	Short term Inhalation	884 mg/m <sup>3</sup>	Workers	Systemic
	DNEL	Long term Oral	1.6 mg/kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	15 mg/m <sup>3</sup>	General population	Systemic
	DNEL	Long term Inhalation	77 mg/m <sup>3</sup>	Workers	Systemic
	DNEL	Long term Dermal	180 mg/kg bw/day	Workers	Systemic
	DNEL	Short term Inhalation	293 mg/m <sup>3</sup>	Workers	Local
Octadecanoic acid,	DNEL	Long term Inhalation	0.055 mg/m <sup>3</sup>	General population	Local
12-hydroxy-, reaction products with ethylenediamine					
	DNEL	Long term Inhalation	0.308 mg/m <sup>3</sup>	Workers	Local

#### **PNECs**

Product/ingredient name	Туре	Compartment Detail	Value	Method Detail
xylene	-	Fresh water	0.327 mg/l	-
	-	Marine water	0.327 mg/l	-
	-	Sewage Treatment Plant	6.58 mg/l	-
	-	Fresh water sediment	12.46 mg/kg dwt	-
	-	Marine water sediment	12.46 mg/kg dwt	-
	-	Soil	2.31 mg/kg	-
o-xylene	-	Fresh water	0.25 mg/l	-
	-	Sediment	14.33 mg/kg	-
	-	Soil	2.41 mg/kg	-
	-	Sewage Treatment Plant	5 mg/l	-
butanone	-	Fresh water	55.8 mg/l	Sensitivity Distribution
	-	Marine water	55.8 mg/l	Sensitivity Distribution
	-	Sewage Treatment Plant	709 mg/l	Sensitivity Distribution
	-	Fresh water sediment	284.74 mg/kg dwt	Equilibrium Partitioning
	-	Marine water sediment	284.7 mg/kg dwt	Equilibrium Partitioning
	-	Soil	22.5 mg/kg dwt	Equilibrium Partitioning
bis-[4-(2,3-epoxipropoxi)phenyl] propane	-	Fresh water	0.006 mg/l	Assessment Factors
	-	Marine water	0.001 mg/l	Assessment Factors
	-	Fresh water sediment	0.996 mg/kg dwt	Equilibrium Partitioning
	-	Marine water sediment	0.1 mg/kg dwt	Equilibrium Partitioning
	-	Soil	0.196 mg/kg dwt	Equilibrium Partitioning
	-	Sewage Treatment Plant	10 mg/l	Assessment Factors
	-	Secondary Poisoning	11 mg/kg	Assessment Factors
ethylbenzene	-	Fresh water	0.1 mg/l	Assessment Factors
	-	Marine water	0.01 mg/l	Assessment Factors
	-	Sewage Treatment Plant	9.6 mg/l	Assessment Factors
	-	Fresh water sediment	13.7 mg/kg dwt	Equilibrium Partitioning
	-	Marine water sediment	1.37 mg/kg dwt	Equilibrium Partitioning
	-	Soil	2.68 mg/kg dwt	Equilibrium Partitioning
	_	Secondary Poisoning	20 mg/kg	-

#### **8.2 Exposure controls**

Appropriate engineering controls

: Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.

#### **Individual protection measures**

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission R	egulation (EU)
2020/878	

Code : 000001199136 FREITAPOX SR 213 EVO BAS	Date of issue/Date of revision : 15 March 2024 E GREY
SECTION 8: Exposur	e controls/personal protection
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	: Chemical splash goggles. Use eye protection according to EN 166.
Skin protection	
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary. Considering the parameters specified by the glove manufacturer, check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated. When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time greater than 480 minutes according to EN 374) is recommended. When only brief contact is expected, a glove with a protection class of 2 or higher (breakthrough time greater than 30 minutes according to EN 374) is recommended. The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.
Gloves	: butyl rubber
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti- static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator. If workers are exposed to concentrations above the exposure limit, they must use appropriate, certified respirators. Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Wear a respirator conforming to EN140. Filter type: organic vapour (Type A) and particulate filter P3
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

# **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

English (GB)	Europe	10/19
Odour threshold	: Not available.	
Odour	: Aromatic. [Slight]	
Colour	: Grey.	
Physical state	: Liquid.	
Appearance		
9.1 Information on basic ph	ysical and chemical properties	

Code : 000001199136 FREITAPOX SR 213 EVO BASE (		ite of issue	e/Date o	f revision	: 1	5 March 2	024
SECTION 9: Physical a	nd chemical pro	perties	;				
Melting point/freezing point	based on data for t	: May start to solidify at the following temperature: 8 to 12°C (46.4 to 53.6°F) This is based on data for the following ingredient: bis-[4-(2,3-epoxipropoxi)phenyl]propane. Weighted average: -60.76°C (-77.4°F)					
Initial boiling point and boiling range	: >37.78°C						
Flammability	: Not available.						
Upper/lower flammability or explosive limits	: Greatest known rar	Greatest known range: Lower: 1.8% Upper: 11.5% (butanone)					
Flash point	: Closed cup: 21°C						
Auto-ignition temperature	· :						
	Ingredient name		°C	°F		Method	
	butanone		404	759.2			
Decomposition temperature	: Stable under recorr	nmended s	torage a	nd handling co	onditions	(see Sec	tion 7)
pH	: Not applicable.	Stable under recommended storage and hand				(000 000	
Viscosity	: Kinematic (40°C): >	>21 mm²/s					
Viscosity	: > 100 s (ISO 6mm)						
Solubility(ies)	:						
Media	Result						
cold water	Not soluble						
Partition coefficient: n-octanol/ water	/ : Not applicable.						
Vapour pressure	:						
•		Vapor	ur Press	ure at 20°C	Vap	our pres	sure at 50°C
	Ingredient name	mm Hg		Method	mm Hg	kPa	Method
	putanone	78.7564	10.5				

	butyl acetate
Relative density	: 1.41
Vapour density	: Highest known value: 11.7 (Air = 1) (bis-[4-(2,3-epoxipropoxi)phenyl]propane). Weighted average: 4.51 (Air = 1)
Explosive properties	: The product itself is not explosive, but the formation of an explosible mixture of vapour or dust with air is possible.
Oxidising properties	: Product does not present an oxidizing hazard.

Particle characteristics

Median particle size 9.2 Other information

**Evaporation rate** 

: Not applicable.

## No additional information.

: Highest known value: 1.5 (isobutyl acetate) Weighted average: 0.78compared with

Code	: 000001199136	Date of issue/Date of revision	: 15 March 2024
FREITAP	OX SR 213 EVO BASE GREY		

# **SECTION 10: Stability and reactivity**

	-	
10.1 Reactivity	:	No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	:	The product is stable.
10.3 Possibility of hazardous reactions	:	Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	:	When exposed to high temperatures may produce hazardous decomposition products. Refer to protective measures listed in sections 7 and 8.
10.5 Incompatible materials	:	Keep away from the following materials to prevent strong exothermic reactions: oxidising agents, strong alkalis, strong acids.
10.6 Hazardous decomposition products	:	Depending on conditions, decomposition products may include the following materials: carbon oxides halogenated compounds metal oxide/oxides

# **SECTION 11: Toxicological information**

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008 Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
xylene	LD50 Dermal	Rabbit	1.7 g/kg	-
	LD50 Oral	Rat	4.3 g/kg	-
o-xylene	LC50 Inhalation Vapour	Rat	27124 mg/m <sup>3</sup>	4 hours
	LD50 Dermal	Rabbit	12126 mg/kg	-
	LD50 Oral	Rat	3523 mg/kg	-
Epoxy Resin (700 <mw<=1100)< td=""><td>LD50 Dermal</td><td>Rat</td><td>&gt;2000 mg/kg</td><td>-</td></mw<=1100)<>	LD50 Dermal	Rat	>2000 mg/kg	-
	LD50 Oral	Rat	>2000 mg/kg	-
butanone	LD50 Dermal	Rabbit	6480 mg/kg	-
	LD50 Oral	Rat	2737 mg/kg	-
bis-[4-(2,3-epoxipropoxi)phenyl]propane	LD50 Dermal	Rabbit	23000 mg/kg	-
	LD50 Oral	Rat	15000 mg/kg	-
sobutyl acetate	LD50 Dermal	Rabbit	>17400 mg/kg	-
2	LD50 Oral	Rat	13400 mg/kg	-
ethylbenzene	LC50 Inhalation Vapour	Rat	17.8 mg/l	4 hours
,	LD50 Dermal	Rabbit	17.8 g/kg	-
	LD50 Oral	Rat	3.5 g/kg	-
Octadecanoic acid, 12-hydroxy-, reaction	LC50 Inhalation Dusts and	Rat	5.05 mg/l	4 hours
products with ethylenediamine	mists		Ŭ	
	LD50 Oral	Rat	>2000 mg/kg	-

**Conclusion/Summary** : There are no data available on the mixture itself.

#### Acute toxicity estimates

Route	ATE value	
Øermal	6978.98 mg/kg	
Inhalation (vapours)	54.41 mg/l	

Irritation/Corrosion

English (GB)	Europe	12/19
--------------	--------	-------

Code : 000001199136 FREITAPOX SR 213 EVO BASE GREY Date of issue/Date of revision

: 15 March 2024

## **SECTION 11: Toxicological information**

Product/ingredient name	Result	Species	Score	Exposure	Observation
xylene bis-[4-(2,3-epoxipropoxi)phenyl]propane	Skin - Moderate irritant Eyes - Mild irritant Eyes - Redness of the conjunctivae Skin - Oedema	Rabbit Rabbit Rabbit Rabbit	- - 0.4 0.5	24 hours 500 mg 24 hours 24 hours 4 hours	- - -
	Skin - Erythema/Eschar Skin - Mild irritant	Rabbit Rabbit	0.8 -	4 hours 4 hours	-

#### Conclusion/Summary

: There are no data available on the mixture itself.

Eyes

Skin

: There are no data available on the mixture itself.

- Respiratory
- : There are no data available on the mixture itself.

#### Sensitisation

Product/ingredient name	Route of exposure	Species	Result
bis-[4-(2,3-epoxipropoxi)phenyl]propane Octadecanoic acid, 12-hydroxy-, reaction products with ethylenediamine		Mouse Guinea pig	Sensitising Sensitising

#### **Conclusion/Summary**

Skin	: There are no data available on the mixture itself.
Respiratory	: There are no data available on the mixture itself.
Mutagenicity	
<b>Conclusion/Summary</b>	: There are no data available on the mixture itself.
<b>Carcinogenicity</b>	
<b>Conclusion/Summary</b>	: There are no data available on the mixture itself.
Reproductive toxicity	
<b>Conclusion/Summary</b>	: There are no data available on the mixture itself.
<b>Teratogenicity</b>	
<b>Conclusion/Summary</b>	: There are no data available on the mixture itself.

#### Specific target organ toxicity (single exposure)

Product/ingredient name		Category	Route of exposure	Target organs	
xylene o-xylene butanone		Category 3 Category 3 Category 3		Respiratory tract irritation Respiratory tract irritation Narcotic effects	
crystalline silica, respirable pow ethylbenzene	der (<10 microns)	Category 1 Category 2	inhalation -	- hearing organs	
nformation on likely : routes of exposure	Not available.				
Potential acute health effects					
Inhalation :	No known significant	effects or critical ha	azards.		
Ingestion :	No known significant	effects or critical ha	azards.		
Skin contact :	Causes skin irritation.	Defatting to the s	kin. May cause ai	n allergic skin reaction.	
Eye contact :	Causes serious eye ir	ritation.			
Symptoms related to the phys	ical, chemical and tox	<u>kicological charac</u>	<u>teristics</u>		

Code : 000001199136 FREITAPOX SR 213 EVO BASE GREY		Date of issue/Date of revision : 15 March 2024		
SECTION 11: Toxico	ogical inform	ation		
Inhalation	: No specific data.			
Ingestion	: No specific data.			
Skin contact	: Adverse symptor irritation redness dryness cracking	ns may include the following:		
Eye contact	: Adverse symptor pain or irritation watering redness	ns may include the following:		
Delayed and immediate effe	cts as well as chroi	nic effects from short and long-term exposure		
<u>Short term exposure</u>				
Potential immediate effects	: Not available.			
Potential delayed effects Long term exposure	: Not available.			
Potential immediate effects	: Not available.			
Potential delayed effects	: Not available.			
Potential chronic health effe	ects			
Not available.				
Conclusion/Summary	: Not available.			
General	repeated contact	ge to organs through prolonged or repeated exposure. Prolonge can defat the skin and lead to irritation, cracking and/or dermatiti a severe allergic reaction may occur when subsequently exposed	s.	
Carcinogenicity	,	cant effects or critical hazards.		
Mutagenicity	: No known signifi	cant effects or critical hazards.		
Reproductive toxicity	: No known signifi	cant effects or critical hazards.		
Other information	: Not available.			

Prolonged or repeated contact may dry skin and cause irritation. Sanding and grinding dusts may be harmful if inhaled. Repeated exposure to high vapor concentrations may cause irritation of the respiratory system and permanent brain and nervous system damage. Inhalation of vapour/aerosol concentrations above the recommended exposure limits causes headaches, drowsiness and nausea and may lead to unconsciousness or death. Avoid contact with skin and clothing.

#### **11.2 Information on other hazards**

#### **11.2.1 Endocrine disrupting properties**

```
Not available.
```

11.2.2 Other information

Not available.

Code : 000001199136 FREITAPOX SR 213 EVO BASE GREY Date of issue/Date of revision

: 15 March 2024

**SECTION 12: Ecological information** 

#### 12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
bis-[4-(2,3-epoxipropoxi)phenyl]propane	Acute LC50 1.8 mg/l Fresh water	Daphnia - <i>daphnia</i> <i>magna</i>	48 hours
	Chronic NOEC 0.3 mg/l	Daphnia	21 days
ethylbenzene	Acute EC50 1.8 mg/l Fresh water	Daphnia	48 hours
	Chronic NOEC 1 mg/l Fresh water	Daphnia - Ceriodaphnia dubia	-
Octadecanoic acid, 12-hydroxy-, reaction products with ethylenediamine	Acute EC50 >100 mg/l	Algae - Pseudokirchneriella subcapitata	72 hours
	Acute EC50 >10 mg/l	Daphnia - Daphnia magna	48 hours
	Acute LC50 >10 mg/l	Fish - Oncorhynchus mykiss	96 hours

**Conclusion/Summary** : There are no data available on the mixture itself.

#### 12.2 Persistence and degradability

Product/ingredient name	Test	Result	Dose	Inoculum
o-xylene ethylbenzene	OECD 301F	94 % - Readily - 28 days 79 % - Readily - 10 days	-	-
Octadecanoic acid, 12-hydroxy-, reaction	301D Ready Biodegradability -	22 % - 28 days	-	-
products with ethylenediamine	Closed Bottle Test			

**Conclusion/Summary** : There are no data available on the mixture itself.

Product/ingredient name	Aquatic half-life	Photolysis	Biodegradability
xylene o-xylene bis-[4-(2,3-epoxipropoxi)phenyl]propane ethylbenzene Octadecanoic acid, 12-hydroxy-, reaction products with ethylenediamine	- - - -	- - - -	Readily Readily Not readily Readily Inherent

#### 12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
xylene	3.12	7.4 to 18.5	Low
o-xylene	3.12	14.13	Low
butanone	0.3	-	Low
isobutyl acetate	2.3	-	Low
ethylbenzene	3.6	79.43	Low
Octadecanoic acid, 12-hydroxy-, reaction products with ethylenediamine	>5.86	-	High

#### 12.4 Mobility in soil

Soil/water partition	
coefficient (Koc)	
Mobility	

: Not available.

Mobility

: Not available.

English (GB)

Europe

Code	: 000001199136	Date of issue/Date of revision	: 15 March 2024
FREITAPC	X SR 213 EVO BASE GREY		

### **SECTION 12: Ecological information**

#### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

#### 12.6 Endocrine disrupting properties

Not available.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

### **SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

#### 13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.

#### European waste catalogue (EWC)

Waste code	Waste designation		
08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances		
Packaging			
Methods of disposal	<ul> <li>The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.</li> </ul>		
Type of packaging	European waste catalogue (EWC)		
Container	15 01 06 mixed packaging		
<ul> <li>Special precautions</li> <li>This material and its container must be disposed of in a safe way. Care show taken when handling emptied containers that have not been cleaned or rinsed Empty containers or liners may retain some product residues. Vapour from presidues may create a highly flammable or explosive atmosphere inside the or Do not cut, weld or grind used containers unless they have been cleaned thos internally. Avoid dispersal of spilt material and runoff and contact with soil, we drains and sewers.</li> </ul>			

# 14. Transport information

Code<th:: 000001199136</th>Date of issue/Date of revision: 15 March 2024FREITAPOX SR 213 EVO BASE GREY

### 14. Transport information

	ADR/RID	ADN	IMDG	ΙΑΤΑ
14.1 UN number or ID number	UN1263	UN1263	UN1263	UN1263
14.2 UN proper shipping name	PAINT	PAINT	PAINT	PAINT
14.3 Transport hazard class(es)	3	3	3	3
14.4 Packing group	II	Ш	Ш	II
14.5 Environmental hazards	No.	Yes.	No.	No.
Marine pollutant substances	Not applicable.	Not applicable.	Not applicable.	Not applicable.

#### **Additional information**

ADR/RID	: None identified.
Tunnel code	: (D/E)
ADN	: The product is only regulated as an environmentally hazardous substance when transported in tank vessels.
IMDG	: None identified.
IATA	: None identified.
14.6 Special pre	ecautions for : Transport within user's premises: always transport in closed containers that are

14.6 Special precautions for	1	<b>Transport within user's premises:</b> always transport in closed containers that are
user		upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

### 14.7 Maritime transport in : Not applicable. bulk according to IMO

#### instruments

## **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>EU Regulation (EC) No. 1907/2006 (REACH)</u> <u>Annex XIV - List of substances subject to authorisation</u>

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions: Not applicable.on the manufacture,<br/>placing on the market<br/>and use of certain<br/>dangerous substances,<br/>mixtures and articles: Not applicable.Explosive precursors: Not applicable.

Ozone depleting substances (1005/2009/EU)

English (GB)

Europe

Code	: 000001199136	Date of issue/Date of revision	: 15 March 2024
FREITAP	OX SR 213 EVO BASE GREY		

#### **SECTION 15: Regulatory information**

Not listed.

#### **Seveso Directive**

This product is controlled under the Seveso Directive.

#### Danger criteria

Category

P5c

### 15.2 Chemical safety

: No Chemical Safety Assessment has been carried out.

#### assessment

SECTION 16: Other information

✓ Indicates information that has changed from previously issued version.

#### Abbreviations and acronyms

ATE = Acute Toxicity Estimate

CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008]

DNEL = Derived No Effect Level

EUH statement = CLP-specific Hazard statement

- PNEC = Predicted No Effect Concentration
- RRN = REACH Registration Number

PBT = Persistent, Bioaccumulative and Toxic

vPvB = Very Persistent and Very Bioaccumulative

ADR = The European Agreement concerning the International Carriage of Dangerous Goods by Road

ADN = European Provisions concerning the International Carriage of Dangerous Goods by Inland Waterway

IMDG = International Maritime Dangerous Goods

IATA = International Air Transport Association

#### Full text of abbreviated H statements

H225	Highly flammable liquid and vapour.
H226	Flammable liquid and vapour.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H372	Causes damage to organs through prolonged or repeated exposure.
H373	May cause damage to organs through prolonged or repeated
	exposure.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
EUH066	Repeated exposure may cause skin dryness or cracking.

Full text of classifications [CLP/GHS]

Code : 000001199136 FREITAPOX SR 213 EVO BASE GREY	Date of issue/Date of revision : 15 March 2024
SECTION 16: Other information	
Acute Tox. 4 Aquatic Chronic 2 Aquatic Chronic 3 Asp. Tox. 1 Eye Irrit. 2 Flam. Liq. 2 Flam. Liq. 3 Skin Irrit. 2 Skin Sens. 1 Skin Sens. 1B STOT RE 1 STOT RE 2 STOT SE 3	ACUTE TOXICITY - Category 4 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3 ASPIRATION HAZARD - Category 1 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2 FLAMMABLE LIQUIDS - Category 2 FLAMMABLE LIQUIDS - Category 3 SKIN CORROSION/IRRITATION - Category 2 SKIN SENSITISATION - Category 1 SKIN SENSITISATION - Category 1B SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 1 SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2 SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE -

#### <u>History</u>

Date of issue/ Date of revision	:	15 March 2024
Date of previous issue	÷	11 September 2023
Prepared by	÷	EHS
Version	:	1.03

#### **Disclaimer**

The information contained in this data sheet is based on present scientific and technical knowledge. The purpose of this information is to draw attention to the health and safety aspects concerning the products supplied by us, and to recommend precautionary measures for the storage and handling of the products. No warranty or guarantee is given in respect of the properties of the products. No liability can be accepted for any failure to observe the precautionary measures described in this data sheet or for any misuse of the products.